Fed Sparks Profit T...
Health Care: Health Services
Trius Therapeutics Inc. (TSRX: NASDAQ)
$7.93 0.03 | 0.38%
05/24/13 - 12:35 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 16.37M | 11.38M | 14.52M | 18.26M |
| Receivables | 5.70M | 4.27M | 1.83M | 689.00K |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 73.98M | 66.69M | 48.56M | 19.42M |
| Property, Plant & Equipment, Gross | 3.83M | 3.28M | 2.49M | 2.18M |
| Accumulated Depreciation & Depletion | 2.84M | 2.24M | 1.79M | 1.69M |
| Property, Plant & Equipment, Net | 990.00K | 1.04M | 701.00K | 494.00K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 303.00K | 401.00K | 240.00K | 1.47M |
| Total Non-Current Assets | 1.29M | 1.44M | 941.00K | 1.96M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 75.27M | 68.12M | 49.50M | 21.38M |
| Accounts Payable | 6.76M | 3.77M | 2.15M | 1.20M |
| Short Term Debt | 0.00 | 0.00 | 0.00 | 69.00K |
| Other Current Liabilities | 3.85M | 7.12M | 0.00 | 0.00 |
| Total Current Liabilities | 18.49M | 18.23M | 3.81M | 1.56M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 0.00 | 0.00 | 238.00K | 20.23M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 0.00 | 0.00 | 238.00K | 71.31M |
| Total Liabilities | 18.49M | 18.23M | 4.05M | 72.88M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 56.79M | 49.89M | 45.45M | -51.50M |
| Common Par | 5.00K | 4.00K | 3.00K | 1.00K |
| Additional Paid In Capital | 206.09M | 145.27M | 122.59M | 1.76M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -149.32M | -95.39M | -77.14M | -53.26M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 9.00K | 7.00K | 0.00 | 0.00 |
| Total Capitalization | 56.79M | 49.89M | 45.45M | -51.50M |
| Total Equity | 56.79M | 49.89M | 45.45M | -51.50M |
| Total Liabilities & Stock Equity | 75.27M | 68.12M | 49.50M | 21.38M |
| Total Common Shares Outstanding | 40.66M | 28.66M | 23.65M | 23.55M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 38.08M | 26.52M | 10.10M | 13.11M |
| Diluted Weighted Shares Outstanding | 38.08M | 26.52M | 10.10M | 13.11M |
| Number of Employees | 90 | 73 | 53 | 36 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with TSRX
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- UserAshley
- ContributorUnder-$10 Setting Up To Tra...
- ContributorStocks Under-$10 Moving Hig...
Latest TSRX Headlines from TheStreet
- Cubist, Optimer, Trius: Antibiotic Deal Making On Tap 05.22.13 | 07:05 am
- Trius Announces Notice Of Allowance Of U.S. Patent Application Related To Tedizolid Phosphate Combination With Daptomycin 05.13.13 | 08:05 am
- Trius Therapeutics Reports First Quarter 2013 Financial Results 05.07.13 | 04:05 pm
- Cramer's Top Stock Picks: BRK.B FB TSRX 05.04.13 | 06:05 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan (Correct) 05.03.13 | 07:05 pm
- Trius Therapeutics Presents Clinical Data On Experimental Antibiotic Tedizolid At ECCMID Meeting 04.29.13 | 08:04 am
- Trius Therapeutics To Present Experimental Antibiotic Study Results At ECCMID Meeting 04.23.13 | 08:04 am
- Trius Appoints Seth Fischer To Its Board Of Directors 04.03.13 | 04:04 pm
- Trius To Present At Future Leaders Conference 04.02.13 | 04:04 pm
- Trius Announces Positive Results From ESTABLISH 2 Study Of Tedizolid In Severe Skin Infections 03.25.13 | 07:03 am
Press Releases for TSRX
- Trius Announces Issuance Of Key U.S. Patent For Torezolid Phosphate - PR Newswire 10.25.10 | 04:10 pm
- Trius To Present At San Diego Biotechnology Network Event - PR Newswire 10.22.10 | 04:10 pm
- Trius To Present At 7th Anti-Infectives Partnering And Deal-Making Summit - PR Newswire 10.06.10 | 04:10 pm
- Trius To Participate In Antibiotics Panel Discussion At Citi's 5th Annual Biotech Day - PR Newswire 10.04.10 | 08:10 am
- Trius Reports New Findings On Mechanisms Of Antibiotic Resistance In MRSA - PR Newswire 09.13.10 | 04:09 pm
- Trius To Present At The Stifel Nicolaus Healthcare Conference - PR Newswire 09.13.10 | 08:09 am
- Trius Therapeutics To Present Data From Drug Development Programs At ICAAC - PR Newswire 09.07.10 | 04:09 pm
- Trius Therapeutics Initiates Phase 3 Program Of Oral Torezolid Phosphate For The Treatment Of ABSSSI - PR Newswire 08.30.10 | 08:08 am
Partner Headlines for TSRX
- Oppenheimer Reiterates Outperform Rating, $12 PT on Trius Therapeutics on 4Q12 EPS - Benzinga 03.13.13 | 01:03 pm
- Trius Therapeutics: New MSRA Treatment Could Bring Billions In Revenues - Seeking Alpha 03.05.13 | 09:03 am
- Who Is Paying Attention To MRSA? - Seeking Alpha 10.23.12 | 09:10 am
- The Company You Keep Speaks Volumes: Novabay And Trius - Seeking Alpha 10.09.12 | 09:10 am
- Big Pharma Abandons Antibiotics: An Opening For Small Biotech - Seeking Alpha 05.13.12 | 09:05 am
- Trius Therapeutics: Outstanding Potential, Discount Price - Seeking Alpha 01.26.12 | 09:01 am
- Company News for May 27, 2011 - Corporate Summary - Zacks 05.27.11 | 10:05 am
- 16 Small Caps With Cash to Cover 1+ Years of Operating Expenses - Seeking Alpha 04.20.11 | 04:04 am
